RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site
ROCKVILLE, Md., Jan. 28, 2016 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has launched its website, www.regentreellc.com. The web site will be an access point for ReGenTree products and technologies and will include updates on clinical trials, regulatory and technology developments, and press releases.
About ReGenTree, LLC
ReGenTree, LLC is a newly created U.S. joint venture company owned by G-treeBNT Co., Ltd., a bio venture company in Korea and RegeneRx Biopharmaceuticals, Inc., a clinical stage drug development company in the USA. As of January 2015, ReGenTree is developing a novel therapeutic peptide, RGN-259 (designated GBT-201 in Korea), in the USA for ophthalmic indications.
G-treeBNT holds a major equity stake in ReGenTree and is responsible for conducting and funding all clinical trials and product development. RegeneRx also holds a significant equity stake in the joint venture, as well as a royalty on future sales of any product developed by the venture, and has contributed all of its related intellectual property and non-clinical and clinical data generated to date. The three-member ReGenTree board of directors includes one member each from the two founding companies and one independent director.
ReGenTree seeks to become a top pharmaceutical company specializing in ophthalmology. It is currently conducting two Phase III clinical trials in the USA to develop treatments for dry eye syndrome and for neurotrophic keratopathy (a rare disease with orphan designation by the USA FDA) with RGN-259/GBT-201. RGN-259/GBT-201 is a sterile, preservative-free eye drop formulation using Blow-Fill-Seal technology and the novel compound, thymosin beta 4 (Tβ4), as its active pharmaceutical ingredient.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 and its constituent fragments, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and has patents and patent applications covering its products in many countries throughout the world. RGN-259, the Company's Tβ4-based ophthalmic drug candidate, has been designated an orphan drug in the U.S. for the treatment of neurotrophic keratopathy (NK). In September 2015, RegeneRx, through its U.S joint venture, ReGenTree LLC, initiated a Phase 2/3 clinical trial in patients with dry eye syndrome and a Phase 3 clinical trial in patients with NK. Both trials are being conducted in the U.S. and are estimated to be completed in early 2016. RGN-259 will also be tested in patients with dry eye syndrome in Asia through RegeneRx's two Asian partnerships. RGN-352, the Company's Tβ4-based injectable formulation, is a Phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar traumatic injuries. For additional information about RegeneRx please visit www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. There can be no assurance that any current or future clinical trials will replicate previous animal or clinical data or result in approved products or future value. All information contained in the ReGenTree web site is current at the time of original publication but there can be no assurance that such information will remain accurate and the Company disclaims any obligation to update information on the ReGenTree website, except as required by applicable law. Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2014, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
SOURCE RegeneRx Biopharmaceuticals, Inc.
Share this article